AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00497484
Drug: recombinant human somatotropin
RxNorm normalized name: Somatotropin (human)
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05689996
Drug: Ozone-Based Agent
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone-based eye drops as adjuvant therapy in microbial keratitis
Trial: NCT06003972
Drug: Copaxone
RxNorm normalized name: Copaxone
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paptients allocated to this arm receive 20 mg GA given s.c daily for a total of 14 days
Trial: NCT03105843
Drug: Mannitol Inhalation Kit
RxNorm normalized name: mannitol inhalation kit
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
Trial: NCT06506955
Drug: futibatinib
RxNorm normalized name: Futibatinib
DrugBank: Futibatinib (DB15149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-120 futibatinib monotherapy
Trial: NCT06506955
Drug: futibatinib, fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TAS-120 futibatinib combination therapy with fulvestrant
Trial: NCT04568616
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aromatase Inhibitor
Trial: NCT06241131
Drug: Desflurane Inhalant Product
RxNorm normalized name: desflurane Inhalant Product
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Desflurane was inhaled at a starting concentration of 1 MAC, and remifentanil 0.1 μg/kg/min was continuously pumped intravenously.
Trial: NCT05021406
Drug: Carvedilol 12.5 MG
RxNorm normalized name: carvedilol 12.5 MG
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol is started at a dose of 6.25 mg once per day, and will increase to a dose of 12.5 mg once per day after 1 week. Target dose will be maintained at 12.5 mg once per day if patients with systolic blood pressure not lower than 90 mm Hg and HR no less than 50 beats/min.
Trial: NCT04433858
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: open-label
Trial: NCT01189032
Drug: DE-089 ophthalmic solution
RxNorm normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02217826
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02217826
Drug: Octreotide
RxNorm normalized name: Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06440629
Drug: Therapeutic drug monitoring (TDM) of adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In the TDM-group, the adalimumab dose will be adjusted according to the following algorithms in order to keep the drug level within the therapeutic range:~* Serum drug level within therapeutic range : keep dose~* Low drug levels, ADAb undetectable or low levels : Decrease dosing interval by one week to a maximum of 40 mg/week~* Low drug levels, ADAb high levels : Switch to another therapy~* High drug levels : Increase dosing interval by one week up to a maximum of 6 weeks
Trial: NCT05261126
Drug: Enclitide Chloride
RxNorm normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enclitide Chloride administered orally
Trial: NCT06137040
Drug: Magnesium Sulfate within the first hour
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The experimental group will receive 40-50 mg/kg of IV magnesium sulfate will be given to the experimental group alongside the first line asthma therapies (ie inhaled beta agonists, IV steroids). This will be given with a 20 mL/kg normal saline bolus (max 1000 mL) to avoid possible hypotension.~15-19 kg: 750 mg~20-29 kg: 1000 mg~30-39 kg: 1500 mg~\>40 kg: 2000 mg
Trial: NCT06390436
Drug: Adalimumab Injection
RxNorm normalized name: adalimumab Injection
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab Injection
Trial: NCT05600855
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Model-predicted high-risk patients: ruxolitinib 5mg bid po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted moderate-risk patients: ruxolitinib 2.5mg bid p po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted low risk: regular aGVHD prophylactic regimens.
Trial: NCT05340465
Drug: Darbepoetin Alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infants in groups 2-5 will be started on Darbe 10 mcg/kg/week between 72 and 84 hours after birth.
Trial: NCT05340465
Drug: Ferumoxytol injection
RxNorm normalized name: ferumoxytol Injection
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Infants in groups 4 and 5 will be given FMX IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
Trial: NCT05766800
Drug: Serplulimab
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05766800
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05766800
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05766800
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05766800
Drug: Liposomal paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05580601
Drug: CIML-NK Cells
RxNorm normalized name: IL15-NK Cell
DrugBank: IL15-NK Cell (DB15725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational cell product is a cytokine-induced memory-like natural killer cell preparation, derived from the recipient's haploidentical donor's apheresis product. At the time of infusion, the product is comprised of:~* Cytokine-Induced Memory-Like NK cells (CIML-NK cells)~* Human Serum Albumin~* Plasmalyte~The concentration and total cell number of CIML-NK cells in the product will vary based on the recipient body weight and the dose requested.
Trial: NCT04562870
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Unit Dose Strength: 20 mg; Dose Formulation: Tablet; Dosage Level: 60 or 80 mg, QW; Route of Administration: Oral
Trial: NCT06262594
Drug: Lemborexant
RxNorm normalized name: Lemborexant
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug is administered
Trial: NCT06584006
Drug: Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections
RxNorm normalized name: Recombinant human interleukin-2
DrugBank: Thymalfasin (DB04900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymalfasin for injection 1.6mg subcutaneous injection once daily (qd) for 7 days, and Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.
Trial: NCT06584006
Drug: Recombinant Human Interleukin-2 Injections
RxNorm normalized name: Recombinant human interleukin-2
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.
Trial: NCT04162756
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered per package insert
Trial: NCT05481151
Drug: Ropeginterferon alfa-2b-njft (P1101)
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ropeginterferon alfa-2b-njft
Trial: NCT05949333
Drug: Eflapegrastim
RxNorm normalized name: Eflapegrastim
DrugBank: Eflapegrastim (DB15001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: long-acting granulocyte-colony stimulating factor
Trial: NCT05494190
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 i.v. day 1
Trial: NCT05494190
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 i.v. day 1-3
Trial: NCT04052854
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib will be orally administered in participants with treatment naive or R/R WM
Trial: NCT05271240
Drug: Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation
RxNorm normalized name: Temozolomide
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects who are assigned to the IA BV+TMZ/RT group (Treatment Group), in addition to your standard of care cancer treatment, you will have a dose of bevacizumab delivered directly to your brain through superselective intra-cranial intra-arterial catheterization of the arteries that supply blood to your brain tumor along with the start of the initial 42 day oral temozolomide treatment. IA BV will be repeated every three months for a total of 3 infusions.
Trial: NCT05271240
Drug: Temozolomide and Radiation Alone
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects who are assigned to the TMZ/RT alone group (Control Group) you will receive standard of care cancer treatment that involves a daily oral dose of temozolomide for 42 days with radiation to the tumor followed by 28 days of rest and then repeated maintenance treatment cycles of daily oral temozolomide 5 days on and 23 days off.
Trial: NCT06263582
Drug: Artesunate pessary
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will use the study pessaries, placed in the vagina every day for 5 consecutive days.
Trial: NCT05899465
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single preoperative intravenous dose and per os treatment postoperatively day 1 through 4
Trial: NCT05899465
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single preoperative intravenous dose and per os treatment postoperatively day 1 through 4
Trial: NCT06377267
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab dosing is at 15 mg/kg every 3 weeks as an intravenous infusion.
Trial: NCT06377267
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib dosing is oral at 300 mg twice daily
Trial: NCT05557110
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Reduced-intensity chemotherapy followed by Blinatumomab
Trial: NCT06669585
Drug: Cannabis (smoked flower)
RxNorm normalized name: CANNABIS SATIVA FLOWERING TOP
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-Directed Use (ad-libitum)
Trial: NCT05084118
Drug: Landiolol HCl
RxNorm normalized name: landiolol HCl
DrugBank: Landiolol (DB12212)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: continous 2mcg/kg/min low dose application of Landiolol HCl for 72 hours
Trial: NCT05929066
Drug: Retatrutide
RxNorm normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06724653
Drug: Beta blocker tapering out
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta blocker tapering out group
Trial: NCT06572930
Drug: Gonal-f (gonadotropin)
RxNorm normalized name: Gonal F
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Women will be given 300 IU Gonal-F daily from cycle day 2 or 3. Gonal F will be injected at 8 pm daily. They will all receive cetrorelix acetate 250 mcg/day (Cetrotide) subcutaneously from stimulation day 5 onwards until and including the trigger day. Cetrotide will be administered at 08:00 am.
Trial: NCT06724289
Drug: Psilocybin 25 mg
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg psilocybin administered to each participant in single arm, open-label trial
Trial: NCT06724237
Drug: High Dose Chemotherapy
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive high dose chemotherapy
Trial: NCT06724237
Drug: Stem Cell Mobilization Therapy
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive stem cell mobilization therapy
Trial: NCT06586983
Drug: Tenofovir Disoproxil Fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg po OD
Trial: NCT06722729
Drug: KDT-3594
RxNorm normalized name: KDT-3594
DrugBank: KDT-3594 (DB17085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT06603857
Drug: CE Ferulic
RxNorm normalized name: ferulate
DrugBank: Ethyl ferulate (DB11285)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE Ferulic serum regimen combined with laser treatment
Trial: NCT06219733
Drug: Vactosertib
RxNorm normalized name: Vactosertib
DrugBank: Vactosertib (DB15310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg PO BID 5 days on / 2 days off
Trial: NCT06219733
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib 400 mg PO QD daily
Trial: NCT06526104
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Priming dose of tremelimumab 300 mg IV once (Cycle 1, Day 1 only)
Trial: NCT06526104
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab 1500 mg IV on Day 1 of each 4-week cycle.
Trial: NCT06177925
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab intravenous infusion will be administered during the induction phase (Cycles 1-2 ) and maintenance phase.
Trial: NCT06177925
Drug: Carboplatin/Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carboplatin/Cisplatin intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
Trial: NCT06177925
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
Trial: NCT05193552
Drug: Hizentra
RxNorm normalized name: Hizentra
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects level of immunoglobulin replacement therapy will be adjusted for bioavailability as per manufacturer's instructions
Trial: NCT05678881
Drug: High dose RLS103
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg CBD inhaled powder
Trial: NCT05678881
Drug: Low dose RLS103
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 mg CBD inhaled powder (open label)
Trial: NCT06381947
Drug: Lipid-lowering therapy combination with PCSK9 inhibitors, bempedoic acid and ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evaluation of therapy of bempedoic acid with PCSK9 inhibitors and ezetimibe in reducing LDL-C in statin-intolerant patients.
Trial: NCT06381947
Drug: Lipid-lowering therapy combination with PCSK9 inhibitors and ezetimibe
RxNorm normalized name: atorvastatin and ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evaluation of therapy of PCSK9 inhibitors with ezetimibe in reducing LDL-C in statin-intolerant patients.
Trial: NCT05199077
Drug: GM-XANTHO
RxNorm normalized name: phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a topical applied ointment
Trial: NCT05165771
Drug: GS-5718
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets administered orally
Trial: NCT05165771
Drug: Tofacitinib 5 mg
RxNorm normalized name: tofacitinib 5 MG
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets administered orally
Trial: NCT05165771
Drug: Placebo to match Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets administered orally
Trial: NCT05372991
Drug: Atropine Sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
Trial: NCT05126966
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab will be administered at a dose of 100 mg/mL delivered via the PDS.
Trial: NCT05126966
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept will be administered at a dose of 2 mg in the study eye per treat-and-extend. The decision to extend, maintain, or reduce the interval until next treatment will be per investigator judgment
Trial: NCT05682716
Drug: Nitroglycerin
RxNorm normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitroglycerin (0.2-1 ug/kg \* min)
Trial: NCT06393504
Drug: Daridorexant
RxNorm normalized name: Daridorexant
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daridorexant received during or shortly prior to pregnancy.
Trial: NCT05800080
Drug: Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy;Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one group receives peri operative treatment of Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy, and the other group receives peri operative treatment of Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy.After receiving corresponding neoadjuvant treatment for 3 cycles according to the established treatment plan, surgical treatment shall be carried out within 3-6 weeks after drug withdrawal
Trial: NCT05141110
Drug: NVP-1705
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP-1705
Trial: NCT04817410
Drug: Emergency Department Initiated Oral Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emergency Department Initiated Oral Naltrexone
Trial: NCT04924608
Drug: Selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib oral capsules (10 mg and 25 mg)
Trial: NCT05228587
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green will be injected in all donor
Trial: NCT04824924
Drug: The combination of HHT, venetoclax, AZA, G-CSF
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HVAG regimen in a 28-day cycle HHT: d1-d7 1mg/m2; VEN: d1 100mg, d2 200mg, d3-d28 400mg; AZA: d1-d7 75mg/m2; G-CSF: d1-d7 300mg
Trial: NCT05828147
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab will be administered as two IV infusions of 1000 mg each, given two weeks apart at Day 0 and Week 2. All subjects will receive 40 mg of prednisone orally the night before and morning of each infusion with diphenhydramine and acetaminophen orally thirty to sixty minutes prior to each infusion of rituximab. Subjects will remain on their baseline standard medical regimen.
Trial: NCT05431673
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500mg/day for 4 weeks used as single or combination treatment for Rhinoscleroma
Trial: NCT05431673
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma